Clarifying the Path to Cash: California Looking for Money from Its Stem Cell Investments
CIRM chart
The $3 billion California stem cell agency is moving to revise its rules for royalties and revenues that may be derived from its research, simplifying them while focusing more sharply on likely cash-generating products.
The proposal comes before the agency's Intellectual Property (IP) Subcommittee Thursday at a 10 a.m. meeting that has a numbe…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.